Installing oncofertility programs for common cancers in optimum resource settings (Repro-Can-OPEN Study Part II): a committee opinion.
Installing oncofertility programs for common cancers in optimum resource settings (Repro-Can-OPEN Study Part II): a committee opinion.
复制标题
DOI：
10.1007/s10815-020-02012-0
复制
发表时间：
2021-01
影响因子：
3.1
通讯作者：
Practice Committee of the Oncofertility Consortium
中科院分区：
文献类型：
--
作者：
Practice Committee of the Oncofertility Consortium
Repro-Can-OPEN研究第2部分的主要目的是了解更多关于最佳资源环境中的肿瘤生育实践，以提供建立肿瘤生育最佳实践模型的路线图。作为在最佳资源环境下的肿瘤生育最佳实践模型的外推，我们调查了来自美国，欧洲，澳大利亚和日本的25个领先和资源充足的肿瘤生育中心和机构。该调查包括关于在儿童癌症、乳腺癌和血癌情况下保留生育能力选择的可用性和利用程度的问题。所有接受调查的中心均回答了所有问题。反应和计算的肿瘤生育力评分显示了在最佳资源设置下肿瘤生育实践的三个主要特征：（1）精子冷冻、卵子冷冻、胚胎冷冻、卵巢组织冷冻、性腺屏蔽和化疗与放疗的分割的强烈利用：（2）GnRH类似物、卵巢固定术、睾丸组织冷冻和卵母细胞体外成熟（IVM）的有前景的利用;新辅助细胞保护性药物治疗、人工卵巢、体外精子发生和干细胞生殖技术的应用很少，因为它们仍处于临床前或早期临床研究阶段。在为患者提供先进的和实验性的肿瘤生育选择时，应考虑适当的技术和伦理问题。我们的Repro-Can-OPEN研究第2部分建议在最佳资源环境中为常见癌症安装特定的肿瘤生育计划，作为最佳实践模型的外推。这将为地球仪的肿瘤生育团队和相关医疗保健提供者提供有效的肿瘤生育启发和建模，并帮助他们为患者提供最好的护理。
The main objective of Repro-Can-OPEN Study Part 2 is to learn more about oncofertility practices in optimum resource settings to provide a roadmap to establish oncofertility best practice models. As an extrapolation for oncofertility best practice models in optimum resource settings, we surveyed 25 leading and well-resourced oncofertility centers and institutions from the USA, Europe, Australia, and Japan. The survey included questions on the availability and degree of utilization of fertility preservation options in case of childhood cancer, breast cancer, and blood cancer. All surveyed centers responded to all questions. Responses and their calculated oncofertility scores showed three major characteristics of oncofertility practice in optimum resource settings: (1) strong utilization of sperm freezing, egg freezing, embryo freezing, ovarian tissue freezing, gonadal shielding, and fractionation of chemo- and radiotherapy; (2) promising utilization of GnRH analogs, oophoropexy, testicular tissue freezing, and oocyte in vitro maturation (IVM); and (3) rare utilization of neoadjuvant cytoprotective pharmacotherapy, artificial ovary, in vitro spermatogenesis, and stem cell reproductive technology as they are still in preclinical or early clinical research settings. Proper technical and ethical concerns should be considered when offering advanced and experimental oncofertility options to patients. Our Repro-Can-OPEN Study Part 2 proposed installing specific oncofertility programs for common cancers in optimum resource settings as an extrapolation for best practice models. This will provide efficient oncofertility edification and modeling to oncofertility teams and related healthcare providers around the globe and help them offer the best care possible to their patients.
登录
查看更多内容
影响因子：
120.7
作者：
Kuchenbaecker, Karoline B.;Hopper, John L.;Antoniou, Antonis C.
通讯作者：
Antoniou, Antonis C.
影响因子：
5.8
作者：
Anazodo, Antoinette;Laws, Paula;Ledger, William
通讯作者：
Ledger, William
影响因子：
4
作者：
Fasano, Giovanna;Dechene, Julie;Demeestere, Isabelle
通讯作者：
Demeestere, Isabelle
影响因子：
4
作者：
Lambertini, Matteo;Di Maio, Massimo;Demeestere, Isabelle
通讯作者：
Demeestere, Isabelle
影响因子：
16.6
作者：
Laronda MM;Rutz AL;Xiao S;Whelan KA;Duncan FE;Roth EW;Woodruff TK;Shah RN
通讯作者：
Shah RN